CA2176191A1 - Promedicaments a base de derives du paclitaxel - Google Patents

Promedicaments a base de derives du paclitaxel

Info

Publication number
CA2176191A1
CA2176191A1 CA002176191A CA2176191A CA2176191A1 CA 2176191 A1 CA2176191 A1 CA 2176191A1 CA 002176191 A CA002176191 A CA 002176191A CA 2176191 A CA2176191 A CA 2176191A CA 2176191 A1 CA2176191 A1 CA 2176191A1
Authority
CA
Canada
Prior art keywords
hydrogen
hydroxy
alkyl
compound
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002176191A
Other languages
English (en)
Inventor
Paul M. Scola
John F. Kadow
Dolatrai M. Vyas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CA2176191A1 publication Critical patent/CA2176191A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6551—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring
    • C07F9/65512—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring condensed with carbocyclic rings or carbocyclic ring systems
CA002176191A 1995-06-06 1996-05-09 Promedicaments a base de derives du paclitaxel Abandoned CA2176191A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46924795A 1995-06-06 1995-06-06
US08/469,247 1995-06-06

Publications (1)

Publication Number Publication Date
CA2176191A1 true CA2176191A1 (fr) 1996-12-07

Family

ID=23863053

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002176191A Abandoned CA2176191A1 (fr) 1995-06-06 1996-05-09 Promedicaments a base de derives du paclitaxel

Country Status (23)

Country Link
EP (1) EP0747385B1 (fr)
JP (1) JPH08337589A (fr)
KR (1) KR100375956B1 (fr)
CN (1) CN1066151C (fr)
AR (1) AR002756A1 (fr)
AT (1) ATE222259T1 (fr)
AU (1) AU695959B2 (fr)
CA (1) CA2176191A1 (fr)
CZ (1) CZ291516B6 (fr)
DE (1) DE69622933T2 (fr)
DK (1) DK0747385T3 (fr)
ES (1) ES2181824T3 (fr)
HU (1) HUP9601524A3 (fr)
IL (1) IL118526A (fr)
MX (1) MX9601994A (fr)
NO (1) NO315233B1 (fr)
NZ (1) NZ286723A (fr)
PL (1) PL187883B1 (fr)
PT (1) PT747385E (fr)
RU (1) RU2162082C2 (fr)
SG (1) SG72692A1 (fr)
TW (1) TW354293B (fr)
ZA (1) ZA964261B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395770B1 (en) * 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
WO1998053811A1 (fr) * 1997-05-27 1998-12-03 Baker Norton Pharmaceuticals, Inc. Methodes et compositions d'administration de taxanes par voie orale a des humains
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6204257B1 (en) * 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
EP1152764A4 (fr) * 1999-02-18 2005-03-23 Oxigene Inc Compositions et procedes servant au ciblage de la destruction vasculaire
US6362172B2 (en) * 2000-01-20 2002-03-26 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
AR030188A1 (es) 2000-02-02 2003-08-13 Univ Florida State Res Found Compuestos de taxano sustituidos con esteres en el c7; composiciones farmaceuticas que los contienen y proceso para tratar un sujeto mamifero que sufre de una condicion que responde a los taxanos
US6780879B2 (en) 2000-02-02 2004-08-24 Fsu Research Foundation, Inc. C7 carbonate substituted taxanes
US6916942B2 (en) 2000-02-03 2005-07-12 Bristol-Myers Squibb Company Process for the preparation of C-4 carbonate taxanes
US6750246B1 (en) 2000-02-03 2004-06-15 Bristol-Myers Squibb Company C-4 carbonate taxanes
US7063977B2 (en) 2001-08-21 2006-06-20 Bristol-Myers Squibb Company Enzymatic resolution of t-butyl taxane derivatives
KR20030049023A (ko) * 2001-12-13 2003-06-25 주식회사 코오롱 방사선 감작제용 파클리탁셀 유도체
CN1960721A (zh) 2004-03-05 2007-05-09 佛罗里达州立大学研究基金有限公司 C7乳酰氧基取代的紫杉烷类
CA2598213C (fr) * 2005-02-18 2011-04-19 Abraxis Bioscience, Inc. Medicaments a hydrophobicite amelioree concus pour etre integres dans des dispositifs medicaux
CA2904054A1 (fr) 2013-03-15 2014-09-25 Concert Pharmaceuticals, Inc. Palbociclib deutere
WO2015009889A1 (fr) 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Dérivés deutériés d'intédanib et leur utilisation pour le traitement de troubles prolifératifs
US20180318268A1 (en) * 2015-11-19 2018-11-08 Biohaven Pharmaceutical Holding Company Ltd. Amine prodrugs of pharmaceutical compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2111527C (fr) * 1992-12-24 2000-07-18 Jerzy Golik Phosphonooxymethylethers de derives du taxane
CA2129288C (fr) * 1993-08-17 2000-05-16 Jerzy Golik Esters phosphonooxymethyliques de derives de taxane

Also Published As

Publication number Publication date
NO962231D0 (no) 1996-05-31
HU9601524D0 (en) 1996-07-29
KR970000222A (ko) 1997-01-21
DK0747385T3 (da) 2002-12-16
CZ156396A3 (en) 1996-12-11
PT747385E (pt) 2002-11-29
CN1144805A (zh) 1997-03-12
ES2181824T3 (es) 2003-03-01
EP0747385B1 (fr) 2002-08-14
TW354293B (en) 1999-03-11
CN1066151C (zh) 2001-05-23
SG72692A1 (en) 2000-05-23
NO315233B1 (no) 2003-08-04
ZA964261B (en) 1997-11-27
ATE222259T1 (de) 2002-08-15
PL187883B1 (pl) 2004-10-29
DE69622933T2 (de) 2003-04-24
NZ286723A (en) 1998-03-25
IL118526A (en) 2001-05-20
HUP9601524A2 (en) 1997-05-28
AU5471896A (en) 1996-12-19
DE69622933D1 (de) 2002-09-19
EP0747385A1 (fr) 1996-12-11
IL118526A0 (en) 1996-10-16
NO962231L (no) 1996-12-09
RU2162082C2 (ru) 2001-01-20
CZ291516B6 (cs) 2003-03-12
KR100375956B1 (ko) 2003-04-21
JPH08337589A (ja) 1996-12-24
PL314637A1 (en) 1996-12-09
MX9601994A (es) 1997-08-30
AU695959B2 (en) 1998-08-27
HUP9601524A3 (en) 2000-03-28
AR002756A1 (es) 1998-04-29

Similar Documents

Publication Publication Date Title
EP0747385B1 (fr) Promédicaments de dérivés du paclitaxel
EP0960107B1 (fr) Paclitaxels a substitution thio en 6
AU722082B2 (en) 6-halo-or nitrate-substituted paclitaxels
US5635531A (en) 3'-aminocarbonyloxy paclitaxels
MXPA96001994A (en) Paclite derivatives profarmacos
EP1251846B1 (fr) Taxanes carbonate en c-4
AU706155B2 (en) 7-deoxy-6-substituted paclitaxels
US5739359A (en) Methods for preparing 1-deoxy paclitaxels
US5840929A (en) C4 methoxy ether derivatives of paclitaxel
EP1263749B1 (fr) Agents anticancereux a base de taxane
AU2001245582A1 (en) Taxane anticancer agents
EP1011329B1 (fr) Paclitaxels 7-methylthiooxomethyle et 7-methylthiodioxomethyle
WO1998047360A1 (fr) Paclitaxels 7-soufre substitues
US6916942B2 (en) Process for the preparation of C-4 carbonate taxanes
WO1999032109A1 (fr) Paclitaxels portant un substituant 7-desoxy-6-azote
WO1998000419A1 (fr) Analogues ortho-ester de paclitaxel

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued